Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: The Toronto experience

Journal Article · Thu Feb 01 00:00:00 EST 1990 · Journal of Clinical Oncology; (USA)

OSTI ID:6937031

Lishner, M; Feld, R; Payne, D G; Sagman, U; Sculier, J P; Pringle, J F; Yeoh, J L; Evans, W K; Shepherd, F A; Maki, E ^[1]

---

1. Princess Margaret Hospital, Toronto, Ontario (Canada)

We retrospectively analyzed the charts of 58 long-term survivors of small-cell lung cancer (SCLC) (greater than 2 years) for neurological complications and their impact on the well-being of these patients. We also attempted to have patients complete a questionnaire regarding any possible neurological problems. This was done in 14 patients. Metastasis to the CNS occurred significantly less often in patients who received prophylactic cranial irradiation (PCI) in a dose of 20 Gy in five equal fractions (two of 48), compared with patients who did not receive it (four of 10) (P less than .006). Delayed neurological complications occurred in nine of 48 (19%) patients who received PCI. However, in only two patients did PCI appear to be responsible for progressive dementia. In the other seven patients (one with weakness in the arms and legs, one with transient left hemiparesis, two with hearing loss, and three with various visual disturbances), chemotherapeutic agents (mainly cisplatin and vincristine) and underlying diseases probably contributed significantly to the occurrence of these complications. In addition, these neurological disturbances were transient or ran a stable course and did not adversely affect the daily life of these patients. In comparison, among the 10 patients who did not receive PCI one had progressive dementia and another had hemiparesis secondary to probable brain embolism. We conclude that the use of PCI in these doses was effective in reducing the frequency of CNS metastases and had an adverse effect on the daily life and well-being only in a minority of the patients. Until results of controlled randomized studies show otherwise, PCI should continue to be used as a part of the combined modality treatment of completely responding patients with limited SCLC.

• OSTI ID: 6937031
• Journal Information: Journal of Clinical Oncology; (USA), Vol. 8:2; ISSN 0732-183X
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
CENTRAL NERVOUS SYSTEM
BIOLOGICAL RADIATION EFFECTS
LUNGS
NEOPLASMS
RADIOTHERAPY
SIDE EFFECTS
ANTINEOPLASTIC DRUGS
FRACTIONATED IRRADIATION
METASTASES
ONTARIO
PATIENTS
RADIATION DOSES
SURVIVAL CURVES
BIOLOGICAL EFFECTS
BODY
CANADA
DISEASES
DOSES
DRUGS
IRRADIATION
MEDICINE
NERVOUS SYSTEM
NORTH AMERICA
NUCLEAR MEDICINE
ORGANS
RADIATION EFFECTS
RADIOLOGY
RESPIRATORY SYSTEM
THERAPY
560151* - Radiation Effects on Animals- Man